References
- Centers for Disease Control and Prevention. HIV and Viral Hepatitis Factsheet; 2014. www.cdc.gov/hiv/pdf/library_factsheets_HIV_and_viral_Hepatitis.pdf. Accessed August 2015.
- Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14:371–386.10.1111/jvh.2007.14.issue-6
- Bica I, McGovern B, Dhar R, et al. Increasing Mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492–497.10.1086/318501
- Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Updated July 2016. Accessed July 2016.
- Cope R, Pickering A, Glowa T, et al. Majority of HIV/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals. AIDS Patient Care STDs. 2015;29:379–383.10.1089/apc.2015.0004
- AASLD-IDSA. Unique patient populations: Patients with HIV/HCV coinfection. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org.
- Sofosbuvir (Sovaldi) [package insert] Gilead. 2013. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Accessed August 2016.
- Simeprevir (Olysio) [package insert] Gilead. 2013. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf. Accessed August 2016.
- Ledipasvir/ sofosbuvir (Harvoni) [package insert] Gilead. 2016. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf. Accessed August 2016.
- Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS clinical trials group. Clin Infect Dis. 2002;34(6):831–837.10.1086/339042
- Wyles DL, Sulkowski MS, Dieterich D. Management of hepatitis C/HIV coinfection in the era of highly effective hepatitis C virus direct-acting antiviral therapy. Clin Infect Dis. 2016;63(Suppl 1):S3–S11.10.1093/cid/ciw219
- Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.10.1056/NEJMoa1501315
- Wyles D, Brau N, et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, April 13–17, 2016. Abstract PS104.
- Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–1231.10.1001/jama.2015.1328
- Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–725.10.1056/NEJMoa1503153